Daewoong Pharmaceutical said Monday that it plans to conduct a Phase III trial of TMPRSS2 inhibitor Foistar, which is targeted at preventing COVID-19, as reported The Korea Herald.
The company recently received an approval from the Ministry of Food and Drug Safety to begin the trial.
Foistar "is expected to work best in the early phase of viral replications. As the drug would hold efficacy against viral mutations, we hope it becomes an optimal preventive measure against further spread of COVID-19," Daewoong said.
In the trial, around 1000 people will be tested to gauge Foistar's preventive effects against the novel coronavirus starting February, the company added.
To read more NewsPoints articles, click here.